{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:18:46Z","timestamp":1760242726980,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"no funding"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>The aim of this study was to assess the usefulness of selective \u03b11-blockers in children with neurogenic urinary tract dysfunctions and increased leak point pressure (LPP). 14 children from age 6 to 16 years with neurogenic urinary tract dysfunctions (neurogenic bladder) and LPP &gt; 40 cm H2O were enrolled in the study. All patients received a selective \u03b11-blocker (doxazosin) for 6\u20138 weeks with an initial dosage of 0.03 mg\/kg. During the observation period the continuation of oral anticholinergics, Clean Intermittent Catheterization (CIC), observation of \u201curinary dryness\u201d and urinary incontinence periods were recommended. Patients were scheduled for a follow-up visit and urodynamic investigation after 6\u20138 weeks after the doxazosin therapy was started. In 4 patients, urine leakage occurred at lower pressures; in 9 patients, no significant changes in urine leak point pressures were detected; in 3 patients, there was a significant increase in the bladder capacity; in one patient, deterioration in continence was noted. The differences both in LPP and LPV before and after the treatment were not statistically significant. Our observations are consistent with the conclusions from other studies and showed no evident efficacy of doxazosin in children with neurogenic bladder.<\/jats:p>","DOI":"10.3390\/ijerph13030321","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T11:10:18Z","timestamp":1458040218000},"page":"321","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["An Evaluation of the Efficacy of Selective Alpha-Blockers in the Treatment of Children with Neurogenic Bladder Dysfunction\u2014Preliminary Findings"],"prefix":"10.3390","volume":"13","author":[{"given":"Pawe\u0142","family":"Kroll","sequence":"first","affiliation":[{"name":"Pediatric Surgery and Urology Department, Neurourology Unit, Pozna\u0144 University of Medical Sciences, ul. Szpitalna 27\/33, Pozna\u0144 60-572, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Gajewska","sequence":"additional","affiliation":[{"name":"Chair for Rheumatology and Rehabilitation, Pozna\u0144 University of Medical Sciences, ul. 28 Czerwca 135\/147, Pozna\u0144 61-545, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Zachwieja","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, Pozna\u0144 University of Medical Sciences, ul. Szpitalna 27\/33, Pozna\u0144 60-572, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Sobieska","sequence":"additional","affiliation":[{"name":"Chair for Rheumatology and Rehabilitation, Pozna\u0144 University of Medical Sciences, ul. 28 Czerwca 135\/147, Pozna\u0144 61-545, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemys\u0142aw","family":"Ma\u0144kowski","sequence":"additional","affiliation":[{"name":"Pediatric Surgery and Urology Department, Neurourology Unit, Pozna\u0144 University of Medical Sciences, ul. Szpitalna 27\/33, Pozna\u0144 60-572, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00467-007-0691-z","article-title":"The neurogenic bladder: Medical treatment","volume":"23","author":"Verpoorten","year":"2008","journal-title":"Pediatr. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-5347(17)54449-3","article-title":"Prognostic value of urodynamic testing in myelodysplastic patients","volume":"136","author":"McGuire","year":"1981","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.juro.2014.01.110","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the Standardization Committee of the International Children\u2019s Continence Society","volume":"191","author":"Austin","year":"2014","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0022-5347(17)57581-3","article-title":"Some alternatives to urinary diversion in children","volume":"119","author":"Hendren","year":"1978","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1464-410X.2005.05638.x","article-title":"Vesicostomy revisited: The best treatment for the hostile bladder in myelodysplastic children?","volume":"97","author":"Morrisroe","year":"2005","journal-title":"BJU"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int."},{"key":"ref_7","first-page":"40","article-title":"Antimuscarinics for the treatment of overactive bladder: Current opinions and emerging therapies","volume":"5","author":"Hegde","year":"2004","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_8","first-page":"169","article-title":"Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group","volume":"157","author":"Hansen","year":"1994","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1185\/03007995.2014.980887","article-title":"General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis","volume":"31","author":"Shim","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jpurol.2011.09.008","article-title":"Tamsulosin for the management of distal ureteral stones in children: A prospective randomized study","volume":"8","author":"Mokhless","year":"2012","journal-title":"J. Pediatr. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.urology.2012.11.031","article-title":"Efficacy of medical expulsive treatment with doxazosin in pediatric patients","volume":"81","author":"Erturhan","year":"2013","journal-title":"Urology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000084623.65480.f8","article-title":"Tamsulosin: Efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury","volume":"170","author":"Abrams","year":"2003","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.urology.2011.10.043","article-title":"Doxazosin versus tizanidine for treatment of dysfunctional voiding in children: A prospective randomized open-labeled trial","volume":"79","author":"Helmy","year":"2012","journal-title":"Urology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0022-5347(01)68067-4","article-title":"Alpha-adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction","volume":"162","author":"Austin","year":"1999","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1590\/S1677-55382004000200010","article-title":"The use and rationale of selective alpha blockade in children with non-neurogenic neurogenic bladder dysfunction","volume":"30","author":"Bogaert","year":"2004","journal-title":"Int. Braz. J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/01.ju.0000085961.27403.4a","article-title":"Alpha blocker therapy for children with dysfunctional voiding and urinary retention","volume":"170","author":"Cain","year":"2003","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.ju.0000135735.49099.8c","article-title":"Primary bladder neck dysfunction in children and adolescents II: Results of treatment with alpha-adrenergic antagonists","volume":"73","author":"Donohoe","year":"2005","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2125.2010.03662.x","article-title":"Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder","volume":"70","author":"Tsuda","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.juro.2011.07.021","article-title":"Phase IIb\/III dose ranging study of tamsulosin as treatment for children with neuropathic bladder","volume":"186","author":"Homsy","year":"2011","journal-title":"J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1464-410X.2002.03008.x","article-title":"Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder","volume":"90","author":"Michael","year":"2002","journal-title":"BJU Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1152\/ajprenal.00573.2014","article-title":"Spinal stimulation of the upper lumbar spinal cord modulates urethral sphincter activity in rats after spinal cord injury","volume":"308","author":"Abud","year":"2015","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0090-4295(03)00754-4","article-title":"Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: Implications for treating stress urinary incontinence","volume":"62","author":"Thor","year":"2003","journal-title":"Urology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1006\/exnr.1999.7124","article-title":"Influence of glutamate receptor antagonists on micturition in rats with spinal cord injury","volume":"159","author":"Yoshiyama","year":"1999","journal-title":"Exp. Neurol."},{"key":"ref_24","first-page":"539","article-title":"Clonidine inhibits vesico-sphincter reflexes in patients with chronic spinal lesions","volume":"72","author":"Herman","year":"1991","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_25","first-page":"35","article-title":"Efficacy of botulinum toxin-A for treating intractable bladder hyperactiviy in children affected by neuropathic bladder secondary to myelomeningocele: An alternative to enterocystoplasty","volume":"57","author":"Marte","year":"2005","journal-title":"Minerva Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","article-title":"A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin","volume":"174","author":"Popat","year":"2005","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S0022-5347(05)00400-3","article-title":"Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele","volume":"175","author":"Altaweel","year":"2006","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/jnnp.63.4.474","article-title":"Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections","volume":"63","author":"Schurch","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.urology.2004.08.016","article-title":"Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra","volume":"65","author":"Smith","year":"2005","journal-title":"Urology"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/13\/3\/321\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:20:43Z","timestamp":1760210443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/13\/3\/321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3]]}},"alternative-id":["ijerph13030321"],"URL":"https:\/\/doi.org\/10.3390\/ijerph13030321","relation":{},"ISSN":["1660-4601"],"issn-type":[{"type":"electronic","value":"1660-4601"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}